Names Thomas Gerson as Chief Financial Officer and James Weaver as Chairman
WALTHAM, Mass., Sept. 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) announced today that Thomas Gerson has been named Chief Financial Officer. The Interleukin Board also appointed James Weaver as Chairman of the Board of Directors. In addition, Nazneen Aziz has joined the company as Vice President, Research and Development.
"We are pleased to welcome Tom to Interleukin," said Thomas Curran, Interim Chief Executive Officer. "Tom's more than 25 years of financial and industry experience, as well as his leadership and strategy skills will help the company focus on our current business objectives. Also, Nazneen is an excellent addition to our research and development team. She will focus primarily on guiding the development of pharmacogenetic and nutrigenetic tests and matching preventive/therapeutic products for medical applications."
Interleukin also announced that current Director James Weaver has been appointed as Chairman of the Board. Mr. Curran will remain on the Board as a Director, and focus on his role as Interim Chief Executive Officer.
Mr. Curran concluded, "With the announcements today, we are confident that Interleukin has a very strong leadership team in place to make progress on our goals. Interleukin is continuing its search to complete this team with the best possible candidate for the role of permanent CEO."
Thomas Gerson has held various financial and leadership roles for more
than 25 years. Most recently he was Chief Financial Officer and VP of
Business Operations at HistoRx, Inc. Previously, he was Chief Financial
Officer, Treasurer and Assistant Secretary at CGI Pharmaceuticals,
|SOURCE Interleukin Genetics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved